| 摘要: |
| 欧洲药品管理局(EMA)于2017年3月发布了关于固定复方药物临床开发的指导原则,该指导原则讨论了固定复方药物临床开发过程中的考虑要点和基本技术要求。我国目前尚无类似文件,通过对该指导原则的介绍,希望对我国固定复方药物的研发和审评工作提供参考。 |
| 关键词: 欧洲药品管理局 固定复方药物 临床开发 指导原则 |
| DOI:10.13506/j.cnki.jpr.2018.09.015 |
| 基金项目: |
|
|
|
| Introduction of the guideline on clinical development of fixed combination medicinal products issued by EMA |
| ZHOU Yu,REN Manru,GONG Xinjiang |
| (Center for Drug Evaluation, China Food and Drug Administration, Beijing 100022, China) |
| Abstract: |
| The European Medicines Agency (EMA) has recently issued an industry guidance on clinical development of fixed combination medicinal products in March 2017. This guideline addresses the considerations and clinical development requirements of fixed combination medicinal products.As there is no guidance regarding this kind of products in China currently,we hope to provide some reference for the research, development and review of fixed combination medicinal products in China by introducing this guidance. |
| Key words: EMA Fixed combination medicinal products Clinical development Guidance |